539 related articles for article (PubMed ID: 17976519)
1. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal changes detected by fluorescence in situ hybridization in patients with acute lymphoblastic leukemia.
Zhang L; Parkhurst JB; Kern WF; Scott KV; Niccum D; Mulvihill JJ; Li S
Chin Med J (Engl); 2003 Sep; 116(9):1298-303. PubMed ID: 14527352
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
4. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
5. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
6. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
8. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
10. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
[TBL] [Abstract][Full Text] [Related]
11. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
[TBL] [Abstract][Full Text] [Related]
12. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
14. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
Hélias C; Struski S; Gervais C; Leymarie V; Mauvieux L; Herbrecht R; Lessard M
Cancer Genet Cytogenet; 2008 Jan; 180(1):51-5. PubMed ID: 18068534
[TBL] [Abstract][Full Text] [Related]
16. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
17. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-positive acute lymphoblastic leukemia: a cytogenetic study of 33 patients diagnosed between 1981 and 2008.
De Braekeleer E; Douet-Guilbert N; Morel F; Le Bris MJ; Basinko A; Berthou C; Morice P; Férec C; De Braekeleer M
Anticancer Res; 2010 Feb; 30(2):569-73. PubMed ID: 20332472
[TBL] [Abstract][Full Text] [Related]
19. Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kumar C; Purandare AV; Lee FY; Lorenzi MV
Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel cryptic translocations involving IGH in B-cell non-Hodgkin's lymphomas.
Gozzetti A; Davis EM; Espinosa R; Fernald AA; Anastasi J; Le Beau MM
Cancer Res; 2002 Oct; 62(19):5523-7. PubMed ID: 12359763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
